RecruitingNot Applicable

Predictors and Prognostic Factors of Myasthenia Gravis Outcome

Egypt30 participantsStarted 2022-01-01

Plain-language summary

This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG. The predictors are including primary outcome (percentage of changes in MG scales at baseline at time of enrollment and after 3 months) and secondary outcome (treatment-related adverse events). Also it aims to determine the frequency of patients with refractory MG. This information will be used to understand the trends and mechanisms of disease relapse, and optimal management strategies.

Who can participate

Age range16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age from 16 years and older.
✓. Gender: both sexes are included.
✓. Clinical Diagnosis of MG with supporting evidence as:
✓. unequivocal clinical response to pyridostigmine
✓. decrement \>10% in repetitive nerve stimulations study (RNS).
✓. Willingness to sample collection, imaging study and other disease-related examinations and assessments.

Exclusion criteria

✕. Age younger than 16 years.
✕. History of chronic psychiatric or neurological disorder other than MG that can produce weakness or fatigue.
✕. Severe systemic illness affecting life-expectancy.

What they're measuring

Change in MG-specific Activities of Daily Living scale (MG-ADL).

Timeframe: The changes in points from baseline assessment score to 3 months follow up assessment score

Change in MG quality of life 15 (MG-QOL15).

Timeframe: The changes in points from baseline assessment score to 3 months follow up assessment score

Change in MG manual muscle testing (MG-MMT).

Timeframe: The changes in points from baseline assessment score to 3 months follow up assessment score

Change in MG composite (MGC) Score.

Timeframe: The changes in points from baseline assessment score to 3 months follow up assessment score

Trial details

NCT IDNCT05214612

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-31

Contact for this trial

Nourelhoda AA Haridy, Lecturer

01063981139 nourelhodaahmed@aun.edu.eg

View on ClinicalTrials.gov More Myasthenia Gravis trials

Plain-language summary

Who can participate

Age range16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age from 16 years and older.
✓. Gender: both sexes are included.
✓. Clinical Diagnosis of MG with supporting evidence as:
✓. unequivocal clinical response to pyridostigmine
✓. decrement \>10% in repetitive nerve stimulations study (RNS).
✓. Willingness to sample collection, imaging study and other disease-related examinations and assessments.

Exclusion criteria

✕. Age younger than 16 years.
✕. History of chronic psychiatric or neurological disorder other than MG that can produce weakness or fatigue.
✕. Severe systemic illness affecting life-expectancy.

What they're measuring

Change in MG-specific Activities of Daily Living scale (MG-ADL).

Timeframe: The changes in points from baseline assessment score to 3 months follow up assessment score

Change in MG quality of life 15 (MG-QOL15).

Timeframe: The changes in points from baseline assessment score to 3 months follow up assessment score

Change in MG manual muscle testing (MG-MMT).

Timeframe: The changes in points from baseline assessment score to 3 months follow up assessment score

Change in MG composite (MGC) Score.

Timeframe: The changes in points from baseline assessment score to 3 months follow up assessment score